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Tablet Splitting: “To Split or Not To Split”
Tablet splitting can save patients money, especially when considering sole-source brand name
products. Yet, the practice of tablet splitting can be problematic as a result of failed therapeutic
outcomes due to over or under dosing. Also, the stability of a medication might be altered or there
may be other unknown reasons not to split a tablet. The following checklist and guide may help
you determine which patients are able to split their own tablets and which tablets might safely be
split.5
A. Patient Considerations:
a. Physical ability:
i. Does the patient or patient’s caregiver have the skill, dexterity, strength, and
visual ability to split a tablet?
No, splitting should not be considered
Yes, go to the next question
b. Cognitive ability:
i. Does the patient or patient’s caregiver have the mental ability to select the
correct medication and split a tablet?
No, splitting should not be considered
Yes, go to the next question
B. Product Considerations (Drug, Potency, and Dosage Form):
a. Is the active ingredient a narrow therapeutic index product (digoxin, levothyroxine,
others)?
Yes, splitting should not be considered
No, go to the next question
b. Is the tablet a controlled- or modified-release product?
Yes, go to the next question
1. Is the tablet scored?
No, splitting should not be considered
Yes, go to the next question
No, go to the next question
c. Does the tablet contain more than one active ingredient?
Yes, splitting should not be considered
No, go to the next question
d. Does the tablet easily break into pieces with minimal handling (friability)?
Yes, splitting should not be considered
No, go to the next question
e. Is the tablet enteric-coated, sublingual, or buccal
or
does it have a poor taste, is it teratogenic if handled, or can it cause mouth irritation?
(See Detail-Document # 241204 “Medications That Should Not be Crushed” for
a helpful list of these medications).
Yes, splitting should not be considered
No, splitting is possible.
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Tablet Splitting: “To Split or Not To Split”
Background
Tablet splitting has been a popular, cost-saving
practice among many patients for years. Patients
have been able to trim prescription costs by
splitting a tablet in halves or quarters. This is
achievable because the prices of some drugs are
similar despite the strength of the tablet. Now,
some HMOs and insurance companies are
utilizing tablet splitting as a cost-saving strategy.
They are implementing policies that often require
patients to split tablets of some commonly used
medications.1,2 A December 2000 class-action
lawsuit in the California court system contends
that Kaiser Permanente has required its health
plan members to split tablets regardless of the
patients’ ability to accurately split tablets and the
products’ suitability for splitting. The lawsuit
states that Kaiser’s tablet-splitting policy is a
violation of the California Business and
Professions Code and the state’s Consumer Legal
Remedies Act.3 National pharmacy and medical
societies have expressed several concerns over
this controversial issue. Primary concerns have
ranged from the patient’s ability to accurately split
the tablet, the content uniformity of the split
tablet, and the possibility of a prescription error if
“1/2 tablet” is misinterpreted as “1-2 tablets.”4-7

Views of Professional Organizations
The American Pharmacists Association and the
American Medical Association are both formally
against mandatory tablet splitting.5 The American
Pharmacists Association (APhA) acknowledges
the widespread practice of tablet splitting, and has
developed a set of guidelines to evaluate the
appropriateness of tablet splitting based on
individual patient and product characteristics.
The APhA suggests tablets that are uncoated and
scored, for example, are often the easiest to split.
Tablets that are round, coated, small, or unscored
may be difficult to split accurately. The patient or
caregiver must also be physically able to divide
the tablet as directed.5-7 The American Society of
Consultant Pharmacists opposes policies that deny

payment for lower strengths of tablet dosage
forms, or policies that mandate tablet splitting by
patients.4 The Department of Veterans Affairs
(VA) has also investigated this issue. Although
the VA did not find specific studies indicating
tablet splitting was detrimental to patients, the VA
does not currently recommend mandatory tablet
splitting.8

Studies
Rosenberg et al evaluated the weightvariability of twenty-two prescriptions containing
560 pharmacist-dispensed split tablet halves. The
United States Pharmacopeia (USP) tablet
uniformity standards require tablets to contain
between 85% and 115% of the labeled dosage,
allowing a 6% relative standard deviation in
overall drug content.
Of the twenty-two
prescriptions tested, only seven (31.8%) met USP
tablet uniformity standards. In addition, five of
the twenty-two products had more than 10% of
their fragments beyond this range.9
In another study, Teng et al evaluated the
accuracy of tablet splitting by a trained individual.
In this study, tablets found to be commonly
divided were split by hand alone and by a singleedged razor blade. The trained individual split
tablets of three products by hand, and tablets of
eleven products with a single-edged razor blade.
The three hand-split tablet groups and eight of the
eleven groups split with a single-edged razor
blade failed to meet USP tablet uniformity
standards.10
Polli, et al examined the issue of tablet
splitting within the Veterans Affairs (VA)
Maryland Healthcare System. In 2001, this
regional VA system promoted tablet splitting of
products including atorvastatin, citalopram,
lovastatin, paroxetine, sertraline, sildenafil, and
simvastatin. Patients, however, could opt out of
the program if they had difficulty splitting the
tablets. The study examined the accuracy of
twelve commonly split tablets.
A trained
pharmacy student split 30 tablets of each product
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using a splitter device provided by the VA, and
the tablet halves were then assessed for weight
uniformity. Eight of the twelve products (67%)
tested passed the USP-based uniformity testing,
while four failed.11
A separate retrospective study by Gee, et al
evaluated the effects of splitting HMG-CoA
reductase inhibitors. A total of 2,019 patients
were enrolled and evaluated on parameters such
as
clinical
effects,
patient
satisfaction,
compliance, and cost issues. The cost avoidance
over a one-year period for splitting atorvastatin,
lovastatin, and simvastatin was estimated to be
$138,108, an average of $68.40 per patient per
year. Of the 454 patients who filled out the
satisfaction questionnaires, 46% believed it was
easier to take medications they did not have to
split. However, 74% believed the tablet splitter
was not too bothersome or time-consuming.
Another 7% believed they had missed more doses
during a month of tablet splitting. Of the 512
patients evaluated for laboratory considerations,
there was no difference in total cholesterol and
triglyceride values before or after tablet splitting
was initiated. Statistically significant differences
did show for AST (26 versus 28, p<0.001), ALT
(24 versus 28, p=0.006), LDL (102 versus 97,
p<0.001), and HDL (46 versus 48, p<0.001) after
the introduction of the tablet splitting process. It
should be noted that the baseline lab panel test
results recorded in the study could range from one
year before to the day of tablet splitting initiation.
Once tablet splitting began, a lab panel could be
obtained between six weeks and one year while in
the splitting phase of the study.12

Conclusion
Mandatory tablet splitting remains a
controversial policy. Because of the variability in
dose that may occur with tablet splitting, this
practice should probably be avoided when
accuracy of the dose is crucial. Enteric-coated
and certain controlled-release tablets are not
intended for splitting. It might be prudent to
contact
the
tablet
manufacturer
before
recommending tablet splitting, when in doubt.
The stability of the medication might be altered or
there may be other unknown reasons not to split a
tablet.
The patient’s individual ability to
accurately split the tablet and the medication itself
should continue to be key concerns.

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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